Arrowstreet Capital, Limited Partnership Exelixis, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $122 Billion
- Q4 2024
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Exelixis, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 3,159,395 shares of EXEL stock, worth $117 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
3,159,395
Previous 1,545,913
104.37%
Holding current value
$117 Million
Previous $40.1 Million
162.26%
% of portfolio
0.09%
Previous 0.03%
Shares
25 transactions
Others Institutions Holding EXEL
# of Institutions
564Shares Held
251MCall Options Held
1.45MPut Options Held
1.13M-
Black Rock Inc. New York, NY33.5MShares$1.24 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.09 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$865 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$565 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$421 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.9B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...